He said: "This is a moment to celebrate British innovation - not only are we responsible for discovering the first treatment to reduce mortality for COVID-19, this vaccine will be made available to some of the poorest regions of the world at a low cost, helping protect countless people from this very bad disease".
British regulators on Wednesday approved a coronavirus vaccine designed by scientists at the University of Oxford.
The British government is set to follow a new vaccination strategy, which will now prioritize giving the first dose, in a series of two, to as many people as possible before distributing the second dose up to 3 months later.
The US Food and Drug Administration (FDA) on December 11 approved the Pfizer-BioNTech COVID-19 vaccine for emergency use.
"As the pandemic rages on, speed of supply is as important as price for vaccines, and here AstraZeneca has been no better than other big pharma companies".
Inoculations with the Pfizer-BioNTech vaccine began in the 27-member bloc over the weekend. Both vaccine treatments require two doses for full effectiveness.
Fatalities linked to COVID-19 in Germany hit a record daily high of 1,129 on Wednesday, bringing total deaths to 32,107, as local authorities caught up with a Christmas reporting backlog.
Which dosage will be used?
Once these blueprints are inside the body they start producing the coronavirus' spike protein, which the immune system recognizes as a threat and tries to squash it. AstraZeneca has said it plans more clinical research to find out whether the results of the half-dose group hold up. The primary efficacy endpoint based on a pooled analysis showed that the vaccine was 70.4% (confidence interval: 54.8% to 80.6%) effective at preventing symptomatic COVID-19 occurring more than 14 days after receiving 2 doses of the vaccine.
Mrs Cameron, who is also the vice-chair of the Stormont Health Committee, added: "This vaccine is significantly easier to store and transport which will enable a more rapid vaccination roll out".
Novavax late this month kicked off a phase 3 study of its recombinant nanoparticle, adjuvanted vaccine in Mexico and the U.S. The study joins a slate of ongoing trials, including a phase 2b assessing safety and efficacy in South Africa, a pivotal phase 3 in the United Kingdom and an ongoing phase 1/2 in the U.S. and Australia. Speaking to ABC 10News, he said that - after receiving the vaccine, his arm was sore for a day but he suffered no other side effects. He noted that the AstraZeneca vaccine "may reach more parts of the world than the Pfizer one".
- Virat Kohli on India's performance at the MCG
- NY health network faces criminal investigation over COVID-19 vaccine
- Messi to miss Barcelona clash with Eibar
- Yemeni officials: Blast at Aden airport kills 25, wounds 110
- First Mutated COVID-19 Strain Detected in Colorado
- Oxford-AstraZeneca COVID-19 vaccine approved in UK
- Despite Fawad, Rizwan’s heroics, New Zealand win first Pakistan Test
- Many injured as natural disaster topples buildings in Croatia
- Gilligan's Island actor Dawn Wells dies aged 82 from COVID-19
- Klopp laments cagey Baggies as Allardyce purrs